ArticleAsian journal of pharmaceutical sciences2026
Mesoporous polydopamine nanoplatform enhances IL-2 immunotherapy for hepatocellular carcinoma via mild photothermal therapy and lactate regulation.
Article in Asian journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is commonly diagnosed at intermediate or advanced stages. While transcatheter arterial embolization (TAE) is the accepted locoregional therapy, embolization inevitably induces severe intratumoral hypoxia, leading to excessive lactate accumulation, metabolic reprogramming and the formation of an immunosuppressive tumor microenvironment (TME), factors that collectively limit durable therapeutic efficacy and promote tumor recurrence. Although immunotherapy has shown promise in HCC, the efficacy of combining TAE with immune-based strategies remains suboptimal, largely due to metabolic constraints and T cell dysfunction within the post-embolization TME. Interleukin-2 (IL-2) therapy can stimulate effector T cells but suffers from the drawbacks of systemic toxicity, a short half-life and TME-induced dysfunction. Recent evidence indicates that lactate-rich, acidic TMEs impair IL-2 stability and signaling, suppress CD8⁺ T cell function, and promote Treg cell activity, thereby further compromising IL-2-based immunotherapy following TAE. Here, we developed a nano-immunotherapy platform (Syr/IL-2@MPDA) using mesoporous polydopamine (MPDA) nanoparticles co-loaded with His-tagged IL-2 and the monocarboxylate transporter inhibitor Syrosingopine (Syr). Syr-mediated lactate regulation alleviates TME acidity and restores IL-2 activity, while MPDA enables mild photothermal therapy (mPTT) to transform immunologically "cold" tumors into "hot" phenotypes, thereby enhancing the immune response. This integrated strategy significantly enhanced antitumor immunity, achieving a tumor growth inhibition rate of 70.87% in a murine subcutaneous tumor model. In an orthotopic N1S1 HCC rat model, the treatment demonstrated strong therapeutic efficacy in combination with αPD-L1 and TAE, overcoming the hazards of TAE-induced lactate accumulation and immune suppression. Overall, this study demonstrates a safe and effective strategy that enhances IL-2 immunotherapy through mPTT and metabolic modulation, offering a promising combination treatment for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.